These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29226391)

  • 1. Experience with leflunomide as treatment and as secondary prophylaxis for cytomegalovirus infection in lung transplant recipients: A case series and review of the literature.
    Silva JT; Pérez-González V; Lopez-Medrano F; Alonso-Moralejo R; Fernández-Ruiz M; San-Juan R; Brañas P; Folgueira MD; Aguado JM; de Pablo-Gafas A
    Clin Transplant; 2018 Feb; 32(2):. PubMed ID: 29226391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature.
    Verkaik NJ; Hoek RA; van Bergeijk H; van Hal PT; Schipper ME; Pas SD; Beersma MF; Boucher CA; Jedema I; Falkenburg F; Hoogsteden HC; van den Blink B; Murk JL
    Transpl Infect Dis; 2013 Dec; 15(6):E243-9. PubMed ID: 24298985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients.
    Gagermeier JP; Rusinak JD; Lurain NS; Alex CG; Dilling DF; Wigfield CH; Love RB
    Transpl Infect Dis; 2014 Dec; 16(6):941-50. PubMed ID: 25491023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
    Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG
    Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
    Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistant Cytomegalovirus Infection in Solid-organ Transplantation: Single-center Experience, Literature Review of Risk Factors, and Proposed Preventive Strategies.
    Majeed A; Latif A; Kapoor V; Sohail A; Florita C; Georgescu A; Zangeneh T
    Transplant Proc; 2018 Dec; 50(10):3756-3762. PubMed ID: 30586840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of Leflunomide in the Treatment of Drug Resistant Cytomegalovirus Retinitis.
    Rifkin LM; Minkus CL; Pursell K; Jumroendararasame C; Goldstein DA
    Ocul Immunol Inflamm; 2017 Feb; 25(1):93-96. PubMed ID: 26652481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
    Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
    J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of leflunomide in renal transplant recipients with ganciclovir-resistant/refractory cytomegalovirus infection: a case series from the University of Chicago.
    Chon WJ; Kadambi PV; Xu C; Becker YT; Witkowski P; Pursell K; Kane B; Josephson MA
    Case Rep Nephrol Dial; 2015; 5(1):96-105. PubMed ID: 26000278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of ganciclovir resistance cytomegalovirus infection with CMV hyperimmune globulin and leflunomide in seven cardiothoracic transplant recipients and literature review.
    Santhanakrishnan K; Yonan N; Iyer K; Callan P; Al-Aloul M; Venkateswaran R
    Transpl Infect Dis; 2022 Feb; 24(1):e13733. PubMed ID: 34534396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes.
    Avery RK; Mossad SB; Poggio E; Lard M; Budev M; Bolwell B; Waldman WJ; Braun W; Mawhorter SD; Fatica R; Krishnamurthi V; Young JB; Shrestha R; Stephany B; Lurain N; Yen-Lieberman B
    Transplantation; 2010 Aug; 90(4):419-26. PubMed ID: 20683281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
    Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
    Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistant cytomegalovirus in intestinal and multivisceral transplant recipients.
    Timpone JG; Yimen M; Cox S; Teran R; Ajluni S; Goldstein D; Fishbein T; Kumar PN; Matsumoto C
    Transpl Infect Dis; 2016 Apr; 18(2):202-9. PubMed ID: 26853894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study.
    Avery RK; Silveira FP; Benedict K; Cleveland AA; Kauffman CA; Schuster MG; Dubberke ER; Husain S; Paterson DL; Chiller T; Pappas P
    Transpl Infect Dis; 2018 Jun; 20(3):e12877. PubMed ID: 29512935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
    Reddy AJ; Zaas AK; Hanson KE; Palmer SM
    J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation.
    Valentine VG; Weill D; Gupta MR; Raper B; Laplace SG; Lombard GA; Bonvillain RW; Taylor DE; Dhillon GS
    J Heart Lung Transplant; 2008 Aug; 27(8):875-81. PubMed ID: 18656801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis.
    Beam E; Lesnick T; Kremers W; Kennedy CC; Razonable RR
    Clin Transplant; 2016 Mar; 30(3):270-8. PubMed ID: 26701733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tailored combined cytomegalovirus management in lung transplantation: a retrospective analysis.
    Solidoro P; Patrucco F; Libertucci D; Verri G; Sidoti F; Curtoni A; Boffini M; Simonato E; Rinaldi M; Cavallo R; Costa C
    Ther Adv Respir Dis; 2019; 13():1753466619878555. PubMed ID: 31566097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection.
    Isada CM; Yen-Lieberman B; Lurain NS; Schilz R; Kohn D; Longworth DL; Taege AJ; Mossad SB; Maurer J; Flechner SM; Mawhorter SD; Braun W; Gordon SM; Schmitt SK; Goldman M; Long J; Haug M; Avery RK
    Transpl Infect Dis; 2002 Dec; 4(4):189-94. PubMed ID: 12535261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Ganciclovir Resistant Cytomegalovirus Retinitis in a Solid Organ Transplant Recipient: A Review of Current Evidence and Treatment Approaches.
    Fu L; Santhanakrishnan K; Al-Aloul M; Jones NP; Steeples LR
    Ocul Immunol Inflamm; 2020 Oct; 28(7):1152-1158. PubMed ID: 31621449
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.